Nicole Lambert
Net Worth
Last updated:
What is Nicole Lambert net worth?
The estimated net worth of Ms. Nicole Lambert is at least $5,101,548 as of 27 Mar 2023. She owns shares worth $1,341,783 as insider, has earned $1,222,215 from insider trading and has received compensation worth at least $2,537,550 in Myriad Genetics, Inc..
What is the salary of Nicole Lambert?
Ms. Nicole Lambert salary is $507,510 per year as Chief Operating Officer in Myriad Genetics, Inc..
How old is Nicole Lambert?
Ms. Nicole Lambert is 51 years old, born in 1974.
What stocks does Nicole Lambert currently own?
As insider, Ms. Nicole Lambert owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Myriad Genetics, Inc. (MYGN) | Chief Operating Officer | 240,506 | $5.58 | $1,341,783 |
What does Myriad Genetics, Inc. do?
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Nicole Lambert insider trading
Myriad Genetics, Inc.
Ms. Nicole Lambert has made 8 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently she sold 6,433 units of MYGN stock worth $151,047 on 27 Mar 2023.
The largest trade she's ever made was exercising 13,184 units of MYGN stock on 2 Mar 2023. As of 27 Mar 2023 she still owns at least 240,506 units of MYGN stock.
Myriad Genetics key executives
Myriad Genetics, Inc. executives and other stock owners filed with the SEC:
- Dr. Jerry S. Lanchbury Ph.D. (66) Chief Scientific Officer
- Mr. Mark S. Verratti (57) Pres of Myriad Neuroscience & Autoimmune
- Mr. Paul J. Diaz (63) Chief Executive Officer, Pres & Director
- Mr. R. Bryan Riggsbee (54) Executive Vice President, Chief Financial Officer & Treasurer
- Ms. Nicole Lambert (51) Chief Operating Officer